Quatre ajuts concedits en la convocatòria amb més propostes presentades
EU empowers four IDIBELL researchers with Marie Sklodowska-Curie Individual Fellowships Read More »
Professor Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona, the Institute of Neurosciences of the UB and the Bellvitge Biomedical Research Institute (IDIBELL), has been awarded the Preclinical Research Award from Cátedra Extraordinaria del Dolor of the University of Salamanca – Grünenthal Foundation. This prize awards a research with animal models, published in the
Last Saturday, January 27th, the Casino of the Center of l’Hospitalet hosted the first Lindibell charity swing jam, the benefits of which will be used to fund some activitites for the young researchers from the Bellvitge Biomedical Research Institute of Bellvitge (IDIBELL). In this first edition, the initiative has raised € 550 thanks to the
Successful first #Lindibell swing jam for biomedical research Read More »
Researchers from the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Àlex Vaquero, have proposed a new regulation mechanism of the NF-κB pathway, which is associated with accelerated cellular aging, based on the analysis of the function of the SirT6 protein. The results of their work, published in
Researchers identify a new NF-kB pathway regulatory mechanism linked to SirT6 Read More »
The group of dr. Conxi Lázaro, principal investigator of the Hereditary cancer research group of the Oncobell program (IDIBELL) and head of the Molecular diagnostic Unit of the Hereditary cancer program (ICO), has been awarded one of five preclinical research grants that NF Research Initiative, an initiative linked to Boston Children Hospital, annually offers. This
Researchers of the Sarcoma group of the Oncobell program – Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. The results of the clinical trial, published in Targeted Oncology, represent a successful step in the translational research strategy
IDIBELL researchers successfully test a new combination therapy in sarcomas Read More »
Researchers of the Molecular Signaling in Cancer group of the Oncobell program (Bellvitge Biomedical Research Institute – IDIBELL) – proCURE Program (Catalan Institute of Oncology – ICO) have described a key cellular receptor in the processes of metastasis in ovarian cancer. The finding, published in Molecular Cancer Therapeutics, might lead to the use of inhibitors
